home / stock / kiadf / kiadf news
Kiadis Pharma N V (KIADF): FY GAAP EPS of -€2.24.Revenue of €21.1MCash and cash equivalents of €13.7MPress Release For further details see: Kiadis Pharma N V reports FY results
Kiadis Pharma N.V. (KIADF) Q2 2020 Results Earnings Conference Call September 30, 2020, 9:00 AM ET Company Participants Amy Sullivan - Senior Vice President, Corporate Affairs Arthur Lahr - Chief Executive Officer Paul van Hagen - Senior Vice President, Finance Conference Call Participants Le...
The following slide deck was published by Kiadis Pharma N.V. in conjunction with their 2020 Q2 earnings call. For further details see: Kiadis Pharma N.V. 2020 Q2 - Results - Earnings Call Presentation
Kiadis Pharma N.V. ( OTC:KIADF ) has granted an exclusive global license to its K-NK004 cell program to Sanofi (NASDAQ: SNY ), including exclusive rights to its K-NK platform for two other preclinical programs (excluding K-NK002 and K-NK003). More news on: Kiadis Pharma N.V., Sanofi, Healt...
The following slide deck was published by Kiadis Pharma N.V. in conjunction with this Read more ...
Kiadis Pharma N.V. (KIADF) Q2 2019 Earnings Conference Call September 10, 2019 9:00 A.M. ET Company Participants Amy Sullivan - Senior Vice President, Corporate Affairs Arthur Lahr - Chief Executive Officer Scott Holmes - Chief Financial Officer Conference Call Participants ...
The following slide deck was published by Kiadis Pharma N.V. in conjunction with their 2019 Q2 earnings Read more ...
Kiadis Pharma N V ( OTC:KIADF ): 1H GAAP EPS of -€1.03. More news on: Kiadis Pharma N.V., Earnings news and commentary, , Read more ...
The following slide deck was published by Kiadis Pharma N.V. in conjunction with this Read more ...